Back20/20 Biolabs Common Stock Overview

20/20 Biolabs Common Stock Total Current Liabilities

Latest total current liabilities for AIDX: $2.6M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$2.58M

Peer average

Loading

20/20 Biolabs Common Stock Total Current Liabilities History

Loading

20/20 Biolabs Common Stock vs. peers: Total Current Liabilities Comparison

Loading

20/20 Biolabs Common Stock Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

20/20 Biolabs Common Stock (AIDX) FAQ

As of the most recent data (March 2026), AIDX shows a total current liabilities of $2.6M. Scroll down for historical charts and peer comparison views.

Tracking AIDX's total current liabilities over time shows whether 20/20 Biolabs Common Stock is scaling, shrinking, or reshaping that part of the business. The current reading is $2.6M Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total current liabilities page, Stockcircle has 20/20 Biolabs Common Stock's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total current liabilities (currently $2.6M) with ownership activity and broader fundamentals.